Fetal allotransplant recipients are resistant to graft-versus-host disease

In utero hematopoietic cell transplantation (IUHCT) is an experimental treatment for inherited immune, metabolic, and hematologic disorders with potential advantages over postnatal hematopoietic cell transplantation (HSCT). In preclinical studies, IUHCT achieves long-term alloengraftment without myeloablation, immunosuppression, or the need for an HLA-matched donor1 –3. Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality after postnatal HSCT4–7 and is the one of the greatest theoretical risks of IUHCT8.

Source: Experimental Hematology - December 16, 2022 Category: Hematology Authors: John S. Riley, Lauren E. McClain, John D. Stratigis, Barbara E. Coons, Sourav K. Bose, Apeksha Dave, Brandon M. White, Haiying Li, Stavros P. Loukogeorgakis, Camila G. Fachin, Andre I.B.S. Dias, Alan W. Flake, William H. Peranteau Source Type: research